No regulatory authority Health Canada, the FDA, the EMA, the TGA, or any equivalent has cleared any of the three component compounds, or the blend formulation, as a drug for human or veterinary use
Please consult a medical professional to determine whether or not Microdosing GLP-1 is appropriate for you
( The safety profile of liraglutide in our cohort was consistent with previous pediatric randomized controlled trials (RCTs), with adverse events (AEs) predominantly mild and gastrointestinal in nature, including nausea, vomiting, and diarrhea, reported in 43.6% of participants ( Despite these favorable outcomes, the discontinuation rate during the dose-escalation phase was relatively high (25.6%), mirroring patterns observed in other pediatric liraglutide trials where treatment withdrawal often occurred during the initial weeks, coinciding with peak gastrointestinal symptoms ( A key strength of this study lies in its conduct within a publicly funded healthcare system, entirely independent of pharmaceutical industry sponsorship, thereby enhancing both methodological rigor and external validity
Theres no FDA-defined microdosing protocol
